Who are Enanta Pharmaceuticals, Inc.'s main suppliers?

Enanta Pharmaceuticals, Inc. (ENTA) key suppliers include: ABBVIE-INC. View the full supplier network at chainsifter.com/chain/ENTA.

Who are Enanta Pharmaceuticals, Inc.'s major customers?

Enanta Pharmaceuticals, Inc. (ENTA) key customers include: ABBVIE-INC, OMERS, Abbott Laboratories, Abbott Laboratories. View the full customer network at chainsifter.com/chain/ENTA.

What sector is Enanta Pharmaceuticals, Inc. in?

Enanta Pharmaceuticals, Inc. (ENTA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

ENTA Supply Chain: Enanta Pharmaceuticals, Inc. Suppliers & Customers

1Suppliers

4Customers

2Debt Items

20Related Chains

Enanta Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ABBVIE-INC	ABBVIE-INC	90%	Under the agreement, we have granted AbbVie an exclusive, worldwide, royalty-bearing license, including a right to grant sublicenses, to specified intellectual property, including several issued U.S.…

Enanta Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
ABBVIE-INC	ABBVIE-INC	92%	AbbVie is responsible for and has funded all costs associated with the development, manufacturing and commercialization of paritaprevir, glecaprevir and any other compounds under this agreement.
OMERS	OMERS	92%	In April 2023, the Company entered into a royalty sale agreement with an affiliate of OMERS, pursuant to which the Company was paid a $ 200,000 cash purchase price in exchange for 54.5 % of future qu…
ABT	Abbott Laboratories	90%	We entered into a Collaborative Development and License Agreement with Abbott Laboratories in November 2006 to develop and commercialize HCV NS3 and NS3/4A protease inhibitors.
ABT	Abbott Laboratories	90%	Reciprocal relationship from ABT graph: Reciprocal relationship from ENTA graph: We entered into a Collaborative Development and License Agreement with Abbott Laboratories in November 2006 to develop…

Enanta Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ENTA-DEBT	Debt stack $186.6M	90%	Market cache reports total debt of $186.6M.
ENTA-DEBT-9316	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2013-09-30.

Enanta Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Enanta Pharmaceuticals, Inc..

Enanta Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
ENTA-OWNER-JANUS-HENDERSON-GROUP-PLC	JANUS HENDERSON GROUP PLC	90%	13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 133 tracked holders.

Enanta Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
MTLS	Materialise NV	100.00	2
NVS	Novartis AG	100.00	2
ITGR	Integer Holdings Corporation	100.00	2
IINN	Inspira Technologies Oxy B.H.N. Ltd.	100.00	2
GRAL	GRAIL, Inc.	100.00	2
NBP	NovaBridge Biosciences	100.00	2
GIFOF	Grifols, S.A.	100.00	2
GIFLF	Grifols, S.A.	100.00	2
ALVO	Alvotech	100.00	2
IVA	Inventiva S.A.	100.00	2
PSNL	Personalis, Inc.	100.00	2
VTAK	Catheter Precision, Inc.	100.00	2
GCTK	GlucoTrack, Inc.	100.00	2
GRFS	Grifols, S.A.	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
FLGT	Fulgent Genetics, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
GIKLY	Grifols, S.A.	100.00	2
EXAS	Exact Sciences Corp	100.00	2
NSPR	InspireMD, Inc.	100.00	2

Enanta Pharmaceuticals, Inc. Supply Chain